174 related articles for article (PubMed ID: 38194777)
1. An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
Huang Y; Jiao Z; Fu Y; Hou Y; Sun J; Hu F; Yu S; Gong K; Liu Y; Zhao G
Eur J Med Chem; 2024 Feb; 265():116121. PubMed ID: 38194777
[TBL] [Abstract][Full Text] [Related]
2. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.
Zhang S; Carlsen L; Hernandez Borrero L; Seyhan AA; Tian X; El-Deiry WS
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454137
[No Abstract] [Full Text] [Related]
3. Recent advances in p53 research and cancer treatment.
Suzuki K; Matsubara H
J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
[TBL] [Abstract][Full Text] [Related]
4. Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease.
Blandino G; Valenti F; Sacconi A; Di Agostino S
Semin Cell Dev Biol; 2020 Feb; 98():105-117. PubMed ID: 31112799
[TBL] [Abstract][Full Text] [Related]
5. Should mutant TP53 be targeted for cancer therapy?
Wang Z; Strasser A; Kelly GL
Cell Death Differ; 2022 May; 29(5):911-920. PubMed ID: 35332311
[TBL] [Abstract][Full Text] [Related]
6. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
7. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
8. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
9. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53: it's not all one and the same.
Kennedy MC; Lowe SW
Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-Mutant P53 Crosstalk in Chemoresistance: A Hint to Monitor Therapy Outcome.
Speciale A; Monti P; Fronza G; Izzotti A; Menichini P
Microrna; 2020; 9(5):322-335. PubMed ID: 33297928
[TBL] [Abstract][Full Text] [Related]
12. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
Kamath D; Iwakuma T; Bossmann SH
Nanomedicine; 2024 Feb; 56():102732. PubMed ID: 38199451
[TBL] [Abstract][Full Text] [Related]
14. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
15.
Di-Iacovo N; Ferracchiato S; Pieroni S; Scopetti D; Castelli M; Piobbico D; Pierucci L; Gargaro M; Chiasserini D; Servillo G; Della-Fazia MA
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731819
[No Abstract] [Full Text] [Related]
16. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
17. Awakening the "guardian of genome": reactivation of mutant p53.
Binayke A; Mishra S; Suman P; Das S; Chander H
Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
[TBL] [Abstract][Full Text] [Related]
18. The dual role of mutant p53 protein in chemosensitivity of human cancers.
Mueller H; Eppenberger U
Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
[TBL] [Abstract][Full Text] [Related]
19. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
20. Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics.
Garg S; Singh J; Verma SR
J Mol Model; 2023 Jan; 29(2):55. PubMed ID: 36700982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
